IRLAB Therapeutics AB (publ) (STO: IRLAB.A)
14.00
-0.40 (-2.78%)
Sep 2, 2024, 10:51 AM CET
IRLAB Therapeutics AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
Cash & Equivalents | 94 | 53 | 32 | 39.9 | 32.8 | 38.7 | Upgrade
|
Cash & Short-Term Investments | 94 | 53 | 32 | 39.9 | 32.8 | 38.7 | Upgrade
|
Cash Growth | 2.17% | 65.63% | -19.80% | 21.65% | -15.25% | -64.43% | Upgrade
|
Accounts Receivable | 163 | 118 | 139 | 144.9 | 126.1 | 151.6 | Upgrade
|
Other Receivables | 32 | 24 | 18 | 13.9 | 7.7 | 19.1 | Upgrade
|
Receivables | 195 | 142 | 157 | 158.8 | 133.8 | 170.7 | Upgrade
|
Inventory | 322 | 338 | 423 | 267.8 | 169.3 | 192.3 | Upgrade
|
Prepaid Expenses | - | 4 | 4 | 3.8 | 3.2 | 3.2 | Upgrade
|
Other Current Assets | - | 64 | - | 1.5 | 1.5 | 1.4 | Upgrade
|
Total Current Assets | 611 | 601 | 616 | 471.8 | 340.6 | 406.3 | Upgrade
|
Property, Plant & Equipment | 388 | 317 | 365 | 239.5 | 247.6 | 274.8 | Upgrade
|
Long-Term Investments | - | - | - | 1.3 | 1.2 | 1.4 | Upgrade
|
Goodwill | 359 | 345 | 363 | 216.4 | 29.4 | 30.3 | Upgrade
|
Other Intangible Assets | 57 | - | - | 42.1 | - | - | Upgrade
|
Long-Term Deferred Tax Assets | - | - | - | - | 3.3 | 0.5 | Upgrade
|
Long-Term Deferred Charges | - | 60 | 79 | - | 15.4 | 12.8 | Upgrade
|
Other Long-Term Assets | - | 10 | 16 | 12.8 | 31.6 | 75.5 | Upgrade
|
Total Assets | 1,415 | 1,333 | 1,439 | 983.9 | 669.1 | 801.6 | Upgrade
|
Accounts Payable | 114 | 60 | 103 | 101.3 | 48.9 | 55.7 | Upgrade
|
Accrued Expenses | - | 34 | 45 | 47.5 | 41.5 | 20.7 | Upgrade
|
Short-Term Debt | - | - | - | 4.8 | - | - | Upgrade
|
Current Portion of Long-Term Debt | - | 18 | 30 | 61.5 | 1.2 | 1.3 | Upgrade
|
Current Portion of Leases | - | 24 | 22 | 19.6 | 21.5 | 24.9 | Upgrade
|
Current Income Taxes Payable | - | - | - | 16.7 | 1.3 | 2.9 | Upgrade
|
Other Current Liabilities | - | 78 | 135 | 65.8 | 36.6 | 49 | Upgrade
|
Total Current Liabilities | 114 | 214 | 335 | 317.2 | 151 | 154.5 | Upgrade
|
Long-Term Debt | 371 | 320 | 318 | 2.2 | 3.5 | 95.4 | Upgrade
|
Long-Term Leases | 67 | 55 | 53 | 28.5 | 22.9 | 45.2 | Upgrade
|
Long-Term Deferred Tax Liabilities | - | 22 | 20 | - | - | - | Upgrade
|
Other Long-Term Liabilities | 213 | 79 | 105 | 96.3 | 7.9 | 10.5 | Upgrade
|
Total Liabilities | 765 | 690 | 831 | 444.2 | 198.4 | 320.8 | Upgrade
|
Common Stock | 650 | 273 | 273 | 273.3 | 273.3 | 273.3 | Upgrade
|
Retained Earnings | - | 355 | 326 | 276.2 | 219.5 | 220.4 | Upgrade
|
Comprensive Income & Other | - | 15 | 9 | -9.8 | -22.1 | -12.9 | Upgrade
|
Total Common Equity | 650 | 643 | 608 | 539.7 | 470.7 | 480.8 | Upgrade
|
Shareholders' Equity | 650 | 643 | 608 | 539.7 | 470.7 | 480.8 | Upgrade
|
Total Liabilities & Equity | 1,415 | 1,333 | 1,439 | 983.9 | 669.1 | 801.6 | Upgrade
|
Total Debt | 438 | 417 | 423 | 116.6 | 49.1 | 166.8 | Upgrade
|
Net Cash (Debt) | -344 | -364 | -391 | -76.7 | -16.3 | -128.1 | Upgrade
|
Net Cash Per Share | -12.40 | -13.15 | -14.13 | -2.77 | -0.60 | -4.69 | Upgrade
|
Filing Date Shares Outstanding | 27.33 | 27.33 | 27.33 | 27.33 | 27.33 | 27.33 | Upgrade
|
Total Common Shares Outstanding | 27.33 | 27.33 | 27.33 | 27.33 | 27.33 | 27.33 | Upgrade
|
Working Capital | 497 | 387 | 281 | 154.6 | 189.6 | 251.8 | Upgrade
|
Book Value Per Share | 23.78 | 23.53 | 22.25 | 19.75 | 17.22 | 17.59 | Upgrade
|
Tangible Book Value | 234 | 298 | 245 | 281.2 | 441.3 | 450.5 | Upgrade
|
Tangible Book Value Per Share | 8.56 | 10.90 | 8.96 | 10.29 | 16.15 | 16.48 | Upgrade
|
Buildings | - | 205 | 205 | 428.4 | 397.6 | 387.2 | Upgrade
|
Machinery | - | 176 | 159 | 1,275 | 1,257 | 1,236 | Upgrade
|
Construction In Progress | - | - | 2 | 1.4 | 0.3 | 2.1 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.